surmount-1 tirzepatide weight loss nondiabetic FDA Grants a New Indication for Obesity Management SURMOUNT-1 Trial - Cardionerds Twitter

The SURMOUNT-1 study was a placebo-controlled 72-week trial in obese subjects that randomized 2,539 participants without diabetes into four equally large study arms with placebo or one of the three tirzepatide doses (5, 10, or 15 mg once weekly)

Insurance coverage, prior authorization requirements, and medication availability vary by plan and may change without notice

While the medication itself is not recognised as a direct cause, certain health conditions, lifestyle factors, and treatment-related changes may increase susceptibility during weight loss

use only under clinician supervision

Common mistakes that undermine tirzepatide results Not everyone who starts tirzepatide achieves the results seen in clinical trials

Ultimately, the decision to switch should be made in consultation with your healthcare provider, who can assess your medical history, current response to tirzepatide, and potential benefits of semaglutide